AstraZeneca CEO says AI is changing drug development and helping increase chances of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop drugs faster and make smarter decisions throughout the research…
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop drugs faster and make smarter decisions throughout the research…
Obesity drug giant Eli Lilly reported a monster first quarter on Thursday, strengthening our conviction to hold the stock after…
We've taken a closer look at Cardinal Health's quarterly results and Thursday's post-settlement conference call. Our conclusion: The 4.9% drop…
CNBC's Jim Cramer said Thursday that investors should look beyond the market's hottest trades and start looking for opportunities in…
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Eli Lilly shares fell 6% on Tuesday and are on track for their worst day since February after a downgrade…
We are buying 90 shares of Cardinal Health at approximately $217. Following the transaction, Jim Cramer's Charitable Trust will own…
Jim Cramer explained Tuesday morning why the Investment Club is trying to strike a delicate balance with its moves during…
Jim Cramer's advice to investors dealing with the fallout from the US-Israeli attack on Iran: be selective. With stocks initially…
We added a new Bullpen name during Friday's monthly meeting, and it has minimal economic sensitivity and faces little to…